Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Are Chinese COVID-19 shots effective against the Delta variant?

06/28/2021 | 11:55pm EDT

BEIJING, June 29 (Reuters) - Many countries from China to Indonesia and Brazil rely heavily on Chinese vaccines to inoculate their people against COVID-19, but there are growing concerns about whether they provide enough protection against the Delta variant, first identified in India.

Below are views from China's health experts about the effectiveness of home-grown vaccines against the Delta, which is becoming the globally dominant variant, and virus preventive measures China is taking.

DO CHINESE VACCINES WORK AGAINST DELTA?

China has not provided vaccine effectiveness results against the variant based on large-scale data in clinical trials or real-world use, nor offered detailed information from lab tests, but Chinese experts are urging people to get inoculated as soon as possible.

The lack of detailed data on the Chinese vaccines against the Delta has hobbled any meaningful peer reviews by foreign experts.

Researchers found that Chinese vaccines are somewhat effective in reducing the risk of symptomatic and severe cases caused by Delta, Zhong Nanshan, a epidemiologist who helped shape China's COVID-19 response, told reporters.

It is based on analysis of infections in Guangzhou city, and Zhong told Reuters the results are preliminary and the sample size is small.

Sinovac spokesman Liu Peicheng told Reuters preliminary results based on blood samples from those vaccinated with its shot showed a three-fold reduction in neutralizing effect against the Delta.

He said a booster shot following the two dose-based regimen could quickly elicit stronger and more durable antibody reaction against the Delta. However, he didn't provide detailed data.

Antibodies triggered by two Chinese vaccines are less effective against the Delta compared with other variants, Feng Zijian, former deputy director at the Chinese Center for Disease Control and Prevention, told state media last week.

Feng did not provide details including the name of the two vaccines.

The shots could still offer protection, since none of those vaccinated in southern Guangdong province, where China's first cases of the Delta variant were found, developed severe symptoms. All severe cases are from unvaccinated people.

Jin Dong-Yan, a virologist at the University of Hong Kong, said Feng's comment alone is not enough to back up the claim that Chinese vaccines are effective against severe cases, as more data is needed.

Indonesia, which has reported record daily cases recently due to a surge in the Delta variant, saw hundreds of medical workers infected by the COVID-19 despite being vaccinated with Sinovac's shot, officials said earlier this month.

It was not immediately clear, however, if the Indonesian medical workers were infected by the Delta variant.

HOW DO THEY COMPARE WITH WESTERN SHOTS?

A study by Public Health England (PHE) found in May the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the Delta two weeks after the second dose.

That compared with 93% effectiveness against the Alpha variant, first identified in Britain.

Two doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the Delta compared with 66% effectiveness against the Alpha, PHE said.

There is no substantial data showing how protective Johnson & Johnson's single-dose COVID-19 vaccine is, and U.S. infectious disease experts are weighing the need for booster shots using mRNA vaccines.

HOW SEVERE WAS THE GUANGDONG OUTBREAK?

Guangdong, China's major manufacturing and export hub, became the country's biggest cluster of Delta cases since reporting its first locally transmitted Delta variant infection in May.

The Delta infections included 146 cases in Guangdong's capital Guangzhou and several cases from the southern tech hub of Shenzhen and nearby Dongguan city.

No new domestic transmissions of any variant have been reported in the province from June 22.

WHAT CHINA HAS DONE?

Guangdong, which has 126 million people, has fast-tracked its vaccination effort since the outbreak. It had administered just 39.15 million doses as of May 19, but the number shot up to 101.12 million by June 20.

Guangzhou, Shenzhen and Dongguan quickly sealed off neighbourhoods where those who were infected and their contacts visited and launched multiple rounds of mass testing, following the protocols observed during previous outbreaks.

The cities also required those travelling out of the province to show proof of negative COVID-19 test results.

Zhong, the epidemiologist, said that without effective control measures 7.3 million people in Guangzhou city would have been infected in the first 20 to 30 days after the initial case. (Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim & Shri Navaratnam)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 6.34% 8550 Delayed Quote.16.86%
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 6.51% 158.93 End-of-day quote.7.45%
EURO / BRAZILIAN REAL (EUR/BRL) 0.75% 6.2914 Delayed Quote.-2.35%
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
09/20SPACE : in Talks to Invest in China's Anhui Province
MT
08/29Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for t..
CI
08/27CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China's Zhifei says unit's COVID shot sho..
RE
08/02Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Cash Dividend o..
CI
07/18CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : Zhifei Biological's COVID-19 Vaccine Reta..
MT
06/28Are Chinese COVID-19 shots effective against the Delta variant?
RE
06/11Chongqing Zhifei Biological Products Co., Ltd. Approves 2020 Profit Distribut..
CI
06/09China to study using CanSinoBIO COVID shots as a booster
RE
05/06Shares of China vaccine makers slump on U.S. waiver support
RE
04/20Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Dividend for th..
CI
More news
Financials
Sales 2021 28 304 M 4 378 M 4 378 M
Net income 2021 5 653 M 874 M 874 M
Net cash 2021 2 777 M 429 M 429 M
P/E ratio 2021 40,7x
Yield 2021 0,58%
Capitalization 254 B 39 327 M 39 330 M
EV / Sales 2021 8,89x
EV / Sales 2022 6,66x
Nbr of Employees 3 380
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 158,93 CNY
Average target price 226,30 CNY
Spread / Average Target 42,4%
EPS Revisions
Managers and Directors
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer & Director
Yu Qin Wu Chairman-Supervisory Board
Bao Kui Liu Independent Director
Gang Deng Independent Director
Sector and Competitors